Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Cash from Investing Activities: 2023-2025

Historic Cash from Investing Activities for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $38.1 million.

  • Monte Rosa Therapeutics' Cash from Investing Activities rose 1.03% to $38.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$67.7 million, marking a year-over-year decrease of 9231.31%. This contributed to the annual value of -$44.5 million for FY2024, which is 150.06% down from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Cash from Investing Activities stood at $38.1 million, which was up 50.60% from $25.3 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' Cash from Investing Activities' 5-year high stood at $38.1 million during Q3 2025, with a 5-year trough of -$100.2 million in Q1 2025.
  • For the 3-year period, Monte Rosa Therapeutics' Cash from Investing Activities averaged around $689,273, with its median value being $18.6 million (2023).
  • Examining YoY changes over the last 5 years, Monte Rosa Therapeutics' Cash from Investing Activities showed a top increase of 141.41% in 2025 and a maximum decrease of 1,117.24% in 2025.
  • Over the past 3 years, Monte Rosa Therapeutics' Cash from Investing Activities (Quarterly) stood at $14.3 million in 2023, then plummeted by 316.10% to -$30.9 million in 2024, then increased by 1.03% to $38.1 million in 2025.
  • Its Cash from Investing Activities was $38.1 million in Q3 2025, compared to $25.3 million in Q2 2025 and -$100.2 million in Q1 2025.